MedTrace Logo

PHARMO Institute Seroquel Safety Study

NCT01342120 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 18325

Last updated 2011-09-02

No results posted yet for this study

Summary

The purpose of this observational study is to study specific outcomes of interest in users of quetiapine compared with all other atypical antipsychotics and specifically olanzapine and risperidone. The outcomes of interest are all-cause mortality, failed suicide attempts, extrapyramidal symptoms, diabetes mellitus, hypothyroidism, acute myocardial infarction and stroke. This retrospective cohort study is based on population-based record linkage system (PHARMO RLS) capturing about 2.5 millions residents in the Netherlands.

Conditions

Sponsors & Collaborators

  • PHARMO Institute for Drug Outcomes Research

    collaborator UNKNOWN

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Edith Heintjes · PHARMO Institute for Drug Outcomes Research

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2010-11-30
Completion
2010-11-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01342120 on ClinicalTrials.gov